Singapore, May 20 -- Charles River Laboratories has announced a new collaboration with MEDIPOST, Inc. focused on advancing Good Manufacturing Practice (GMP) testing solutions for cell therapies.

Established through a non exclusive Memorandum of Understanding (MOU), the collaboration will support the growing global demand for high quality, reliable testing services required for the development and commercialisation of advanced cell and gene therapies.

Under the agreement, both organisations will work together to strengthen GMP testing capabilities designed to support therapy developers across various stages of the product lifecycle, helping accelerate the transition of innovative cell therapies from laboratory research to clinical and co...